Quelling of Excitotoxicity in Acute Stroke With Ketamine
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.
Also called NCT03223220
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 120 participants
- Sponsor
- Lower Merion Neurology Research Foundation
- Registry
-
NCT03223220
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT03223220. Randomized; quadruple masking; primary purpose treatment. Start 2024-07-01 (anticipated); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Quelling of Excitotoxicity in Acute Stroke With Ketamine
- Acronym
- QUEST-KETA
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Ketamine
- Intervention (Other)
- Normal Saline
- Intervention (Drug)
- Midazolam injection
- Lead sponsor
- Lower Merion Neurology Research Foundation
Record details
- Record id
cardio:ct-nct03223220- Content hash
9c090758b1aa1d9013fe6a25b2194bec3f212209dd21508be9c2ff44009ed674